chronic kidney disease with type 2 diabetes
Endocrinology · 2022–2022
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| finerenone Treatment of chronic kidney disease with type 2 diabetes, for delay of progressive decline of kidney function and reduction of cardiovascular mortality and… | Jul 2022 | Not recommended | input received Diabetes Australia |
Who spoke
Diabetes Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.